Laevoroc Medical

Laevoroc is a Swiss clinical-stage biotechnology company dedicated to developing next-generation precision oncology therapies by targeting the purinergic signaling pathway. The company focuses on modulating the tumor microenvironment to overcome immune suppression and enhance the efficacy of cancer treatments. Its lead asset, LR06, is a potent and selective small molecule inhibitor of CD73 currently being evaluated in Phase 1/2 clinical trials for various solid tumors. Laevoroc operates through a group structure, including specialized subsidiaries like Laevoroc Oncology and Laevoroc Immunology, to advance its pipeline of purinergic signaling modulators. The company's approach combines deep expertise in adenosine biology with a focus on high unmet medical needs in oncology.